Intravitreal fluocinolone implant shows efficacy in diabetic macular edema but complications common

Two-year results from a multicenter, randomized, masked trial show a0.5 mg fluocinolone acetonide sustained-release, intravitreal implant issignificantly more effective in resolving retinal thickening at the centerof the macula and improving visual acuity in eyes with diabetic macularedema compared with standard of care. However, the steroid has also beenassociated with high rates of cataract progression and increased IOP, reportedAndy Pearson, MD.